2 weeks Ago By Defense World Staff
JPMorgan Chase & Co. raised its stake in shares of Bioventus Inc. (NYSE:BVS – Free Report) by 17.
9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 299,130 shares of the company’s stock after acquiring an additional 45,390 shares during the quarter. JPMorgan Chase & Co.
owned approximately 0.37% of Bioventus worth $3,141,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also made changes to their positions in the company.
Prudential Financial Inc. grew its stake in Bioventus by 650.5% in the fourth quarter.
Prudential Financial Inc. now owns 88,260 shares of the company’s stock valued at $927,000 after purchasing an additional 76,500 shares during the last quarter. Sheets Smith Investment Management purchased a new stake in shares of Bioventus in the 4th quarter valued at $1,499,000.
Vanguard Group Inc. boosted its stake in shares of Bioventus by 18.7% in the fourth quarter.
Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after buying an additional 388,174 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Bioventus in the fourth quarter valued at $75,000.
Finally, American Century Companies Inc. grew its holdings in Bioventus by 38.7% in the fourth quarter.
American Century Companies Inc. now owns 884,673 shares of the company’s stock valued at $9,289,000 after purchasing an additional 246,645 shares during the period. 62.
94% of the stock is currently owned by hedge funds and other institutional investors. Bioventus Trading Down 4.1 %BVS opened at $7.
50 on Tuesday. Bioventus Inc. has a one year low of $3.
90 and a one year high of $14.38. The business’s 50 day moving average price is $9.
24 and its 200 day moving average price is $10.56. The stock has a market capitalization of $614.
58 million, a PE ratio of -12.29 and a beta of 0.92.
The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.
41. Insider Buying and SellingIn other news, SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.
19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.
82. This trade represents a 3.57 % decrease in their position.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Leonard Singleton sold 3,875 shares of Bioventus stock in a transaction on Friday, April 11th. The stock was sold at an average price of $7.
57, for a total transaction of $29,333.75. Following the sale, the chief financial officer now owns 141,088 shares in the company, valued at $1,068,036.
16. This represents a 2.67 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,208 shares of company stock valued at $226,138. 32.
90% of the stock is currently owned by insiders. Wall Street Analysts Forecast GrowthSeparately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th.
Get Our Latest Analysis on BioventusBioventus Profile (Free Report)Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.Read MoreFive stocks we like better than BioventusWhat is the FTSE 100 index? AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockHow to Effectively Use the MarketBeat Ratings ScreenerWhy Call Option Traders Are Targeting This Dividend ETF NowHow to Use the MarketBeat Stock Screener Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying.
